In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the ...

The FDA has announced its first approval for an Ebola treatment that can be used with both pediatric and adult patients infected by Zaire ebolavirus. The treatment is called Inmazeb; it is comprised ...

The Food and Drug Administration (FDA) announced the first-ever approval of an Ebola drug, which is made of three monoclonal antibodies. The drug, Inmazeb, was developed by Regeneron Pharmaceuticals ...

(RTTNews) - The U.S. Food and Drug Administration has approved Inmazeb, an antibody cocktail made by Regeneron Pharmaceuticals Inc. (REGN), for the treatment of infection caused by Zaire ebolavirus ...

Atoltivimab, maftivimab, and odesivimab-ebgn is a combination of Zaire ebolavirus glycoprotein directed recombinant human IgG1 human monoclonal antibodies. The Food and Drug Administration (FDA) has ...

Regeneron’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn combination) has been approved as the first treatment for Zaire ebolavirus (Ebola virus) infection in adults and children. The therapy ...

Jack has a degree in Medical Genetics from the University of Leicester.View full profile Jack has a degree in Medical Genetics from the University of Leicester. The novel treatment helps stave off the ...